Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patientsMasaki Shiota, Naoki Terada, Toshihiro Saito et al.|Cancer Science|2020Cited by 48
Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology eraKazuyuki Numakura, Tomonori Habuchi, Yumin Muto et al.|Cancer Medicine|2021Cited by 22
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancerNaoki Terada, Takashi Mizowaki, Toshihiro Saito et al.|BJUI Compass|2020Cited by 19
Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.Funda Meric‐Bernstam, Takahiro Kojima, Jeannie Hoffman-Censits et al.|Journal of Clinical Oncology|2025Cited by 15
Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancerMasaki Shiota, Naoki Terada, Hiroshi Kitamura et al.|Cancer Science|2021Cited by 15